Filing summary
Period and entity: The supplied filing is NeoStem, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a Lisata Therapeutics filing or a 2013 Q1 report. The company combined cell-therapy development with revenue-generating contract development and manufacturing services through PCT.
Key financial results
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Revenue | $4.06 million | $2.52 million, up 61% |
| Gross profit and margin | Approximately $0.23 million; 6% | Approximately $0.13 million; 5% |
| Operating expenses | $17.55 million | $11.36 million, up 55% |
| Operating loss | $13.50 million | $8.83 million |
| Net loss | $13.83 million | $8.86 million |
| Net loss attributable to common stockholders / diluted loss per share | $13.68 million / $0.49 | $8.80 million / $0.53 |
| Operating cash flow | $(11.25) million | $(7.14) million |
| Investing cash flow | $(1.24) million | $(0.05) million |
| Financing cash flow | $7.72 million | $2.71 million |
| Cash and cash equivalents, quarter-end | $41.36 million | $46.13 million at Dec. 31, 2013 |
| Working capital, quarter-end | Approximately $37.8 million | Not clearly stated for the comparable quarter |
| Debt, quarter-end | $1.71 million notes and $3.18 million mortgages | Notes and mortgages totaled approximately $4.15 million at Dec. 31, 2013 |
Changes, outlook, and risks
- Revenue growth was led by PCT clinical services: clinical services revenue rose 88%, while processing and storage revenue declined 7%. Growth included more active clinical-service clients and completion of a large process-development contract; about $1.5 million of process-development revenue remained deferred pending contract completion.
- Research and development expense increased 50% to $4.76 million, including greater spending on the Treg platform and AMR-001. Selling, general and administrative expense rose 55% to $8.97 million; higher stock-based compensation and corporate-development activity were significant factors. Total stock-based compensation was $3.89 million versus $2.22 million.
- Cash declined by $4.77 million during the quarter. The company raised $5.63 million from common-stock sales under its Aspire agreement and $1.28 million from warrant exercises. A new Aspire stock-purchase agreement provided for up to $30 million over 24 months, subject to its terms.
- Management expected existing cash, revenue and access to the Aspire agreement to fund the business as then operated into 2015, but said additional capital would be needed for development and expansion. The planned Melapuldencel-T Phase 3 trial was expected to start in 2014 and cost approximately $25 million; the acquisition could require reprioritizing other trials. Financing may be unavailable or dilutive, and insufficient capital could delay or halt programs.
- Clinical plans included analysis of the completed 160-patient PreSERVE AMI Phase 2 trial after six-month follow-up, expected in June 2014, and planned 2014 Treg studies in type 1 diabetes and steroid-resistant asthma. These are forward-looking plans, not guarantees.
- After quarter-end, on May 8, 2014, NeoStem acquired California Stem Cell, renamed NeoStem Oncology, issuing 5,329,593 shares and agreeing to potential milestone consideration of up to $90 million in cash or stock. Melapuldencel-T’s planned 250-patient Phase 3 protocol had an FDA Special Protocol Assessment; the filing also describes Fast Track and Orphan Drug designations.
- Other notable items include a $190,000 increase in acquisition-related contingent consideration, bringing that liability to $9.64 million, and a minimum unencumbered-liquidity covenant on mortgages, with the company reporting compliance. The filing reports no material changes to previously disclosed legal proceedings or risk factors, while noting additional risks from the CSC acquisition.
Important facts to verify
- Confirm the intended issuer and period: the source is NeoStem’s quarter ended March 31, 2014, despite the request metadata naming Lisata and 2013 Q1.
- Review the CSC merger terms, share issuance, potential milestone payments, and the acquisition’s effect on cash needs and dilution.
- Track operating cash burn, available funding under the Aspire agreement, and whether financing supports the stated runway and planned clinical programs.
- Verify progress and costs for the Melapuldencel-T Phase 3 trial, PreSERVE AMI data analysis, and planned Treg trials.
- Assess the durability and margins of PCT revenue, including the timing of completed-contract process-development revenue and customer activity.